tirzepatide and glp 1 the same Associated with Lower POAG, OHT Risk Compared with Other GLP-1 Drugs Comparison between GLP-1 RA and

Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population

Clinical trials on Indian adult patients with type 2 diabetes mellitus over a 24-week period have demonstrated Lirafit to be effective, safe and well-tolerated

ORDER FLOW Three steps from cart to tirzepatide on your bench Pick your tirzepatide vial Choose between 10 mg, 15 mg, 30 mg, 45 mg, 60 mg or 100 mg per-mg cost drops as the vial size scales

It is a progressive disease

Tirzepatide interacts with gut receptors that influence motility, secretion, and inflammation